Related Experiment Video
Updated: Jul 10, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Atrial fibrillation and stroke prevention
Gregory Y H Lip1, Hoong Sern Lim
1University Department of Medicine, City Hospital, Birmingham, UK. g.y.h.lip@bham.ac.uk
Insights
Anticoagulant therapy effectively prevents stroke in atrial fibrillation (AF) patients, especially the elderly. However, this stroke prevention treatment is underused due to concerns about bleeding risks and uncertain thromboembolism risk assessment.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a prevalent arrhythmia linked to significant stroke and thromboembolism risk.
- Anticoagulant therapy is proven to reduce stroke risk, with greatest benefit in high-risk individuals.
- Despite proven benefits, anticoagulant use, particularly in the elderly, remains suboptimal.
Purpose of the Study:
- To review evidence supporting and opposing warfarin and aspirin for stroke prevention in AF.
- To discuss clinical assessments and risk stratification for guiding antithrombotic therapy in AF patients.
- To explore barriers hindering the adoption of anticoagulation therapy for stroke prevention.
Main Methods:
- Literature review of studies on warfarin and aspirin for stroke prevention in AF.
- Analysis of clinical trial data regarding benefits and risks of anticoagulation.
- Discussion of risk stratification tools and clinical guidelines.
Main Results:
- Anticoagulant therapy significantly reduces stroke risk in AF patients.
- Aspirin offers less effective stroke prevention compared to anticoagulants.
- Underuse of anticoagulation may stem from perceived risks and uncertain individual risk assessment.
Conclusions:
- Anticoagulant therapy is crucial for stroke prevention in AF, particularly for the elderly.
- Addressing barriers to anticoagulation uptake is essential for improving patient outcomes.
- Risk-benefit assessment and patient selection are key to optimizing antithrombotic therapy.
Abstract:
Atrial fibrillation (AF) is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Anticoagulant therapy reduces the risk of stroke, and the greatest benefit is seen in patients at highest absolute risk. Aspirin is a less effective alternative, and any benefit of aspirin might be due to its favourable effects on arterial thrombosis caused by vascular disease. However, anticoagulant therapy remains underused, particularly in the elderly, who probably have the most to gain from stroke prevention owing to their high absolute risk. The underuse of anticoagulation might also be related to uncertain risk of thromboembolism in individual patients and a perceived overestimation of the benefit and underestimation of risk of bleeding with warfarin in clinical trials. In this Review, we summarise the data for and against warfarin and aspirin therapies and discuss the clinical assessments and risk stratifications that guide the use of antithrombotic therapy for stroke prevention in patients with AF. Possible barriers to the uptake of anticoagulation therapy are also discussed.
More Related Videos
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Coronary Artery Disease IV: Preventive Measures

